BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TQA3605 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of TQA3605\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07797231-9845@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:TQA3605: Phase 3 readout est. (NCT07797231)
DESCRIPTION:TQA3605\, phase 3\, Chronic Hepatitis B.\nStudy: Clinical Trial
  of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus
  NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus In
 fection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Re
 sponse\nEstimated primary completion: September 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/tqa3605#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07797231
URL:https://assetmemo.bio/drug/tqa3605#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
